SECsense Logo

Regeneron Pharmaceuticals 8-K Report: Latest Updates on Compliance & Stock Performance

$REGN
Form 8-K
Filed on: 2025-06-18
Source
Regeneron Pharmaceuticals 8-K Report: Latest Updates on Compliance & Stock Performance

Here’s the key information extracted from the financial report section provided:

  1. Entity Information:
  • Company Name: Regeneron Pharmaceuticals, Inc.
  • CIK Number: 0000872589
  • IRS Number: 13-3444607
  • Address: 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707
  • Phone Number: 914-847-7000
  • Ticker Symbol: REGN
  • Exchange: NASDAQ
  1. Filing Information:
  • Filing Type: 8-K (Current Report)
  • Filing Date: June 13, 2025
  • Period Covered: June 13, 2025
  1. Stock Information:
  • Common Stock: Par value of $0.001 per share.
  • Units of Measurement:
    • USD (United States Dollar)
    • Shares
  1. Context:
  • The filing is a current report (8-K) which typically discloses unscheduled material events or corporate changes that are important to shareholders.

Insights:

  • The company is actively filing reports with the SEC, indicating a commitment to transparency and compliance with regulatory requirements.
  • The par value of the common stock is relatively low, which is common among technology and biotech firms, allowing for flexibility in equity financing.
  • The filing date suggests that the information is relevant to events occurring as of the same day, which may impact investor perception and market activity.

Overall, this section provides critical identification and filing information pertinent to investors and analysts monitoring Regeneron Pharmaceuticals, particularly related to its compliance and stock performance.